SCHEMBL12464243

SCHEMBL12464243

CCCCOc1cc(C(=O)O)c(Br)cc1OC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.71
FYN P06241 1/20 0.71
TSHR P16473 1/20 0.65
HSD17B10 Q99714 1/20 0.65
TP53 P04637 1/20 0.47
LMNA P02545 1/20 0.45
CNR2 P34972 1/20 0.45
SMPD1 P17405 3/20 0.45
PTPN11 Q06124 3/20 0.45
S1PR3 Q99500 1/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
PLA2G4B P0C869 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
PTGES O14684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18710473 0.87 LCK (0.51) LCKFYNTSHRHSD17B10LMNA
SCHEMBL12085119 0.85 TP53 (0.53) LCKFYNTSHRHSD17B10TP53
SCHEMBL307832 0.84 LCK (1.00) LCKFYNTSHRHSD17B10KDM4E
SCHEMBL13299048 0.84 TP53 (0.48) LCKFYNTP53CNR2SMPD1
SCHEMBL13299069 0.82 KDM4E (0.51) LCKFYNTP53CNR2SMPD1
SCHEMBL13257727 0.82 KDM4E (0.51) LCKFYNTP53CNR2SMPD1
SCHEMBL73150 0.82 RARA (0.49) LCKFYNTP53CNR2SMPD1
SCHEMBL8167721 0.81 PTPN11 (0.61) TSHRHSD17B10TP53PTPN11S1PR3
SCHEMBL10268417 0.80 TSHR (0.51) TSHRHSD17B10TP53PTPN11S1PR3
SCHEMBL17054339 0.79 LCK (0.44) LCKFYNTSHRHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985879-B2 reacting a 5-hydroxy-4-methoxy benzoic acid derivative with N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine, to form N-methyl-N-(2-[4-hydroxyphenyl]ethyl)-5-hydroxy-4-methoxy benzene carboxamide, which is useful as an intermediate in the synthesis of lycoremine SCINOPHARM TAIWAN LTD. (TW) 2011-07-26 US disclosed
US-20080255347-A1 Process for making galantamine SCINOPHARM TAIWAN LTD. 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255347-A1 Process for making galantamine GALR2, GALE, GALR1 LCK 4656/4885FYN 2731/4885TSHR 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.